Vertex Pharmaceuticals is giving 340B covered entities refunds for overcharges from Q2 2021 through Q4 2021 on its cystic fibrosis combination medicine Trikafta.
Vertex Providing Refunds for 340B Overcharges on Cystic Fibrosis Drug Trikafta
Biopharmaceutical company Vertex is providing refunds to 340B covered entities for overcharges on its cystic fibrosis (CF) combination medicine Trikafta for the period from Q2 2021 through Q4 2021, according to a public notice on the U.S. Health Resources and Services Administration website.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.